New Research Progress on VG301 Development

Virogin’s R&D team announced good news just after New Year’s Eve in 2023. Virogin’s global R&D team released the preprint of “HSV-1 Oncolytic Virus Targeting CEACAM6-Expressing Tumors Using a Bispecific T Cell Engager” on BioRxiv. This article focuses on the latest research progress of the company’s newest generation of oncolytic virus product VG301 (product code […]